Evogene Reports Second Quarter 2025 Financial Results
21 August 2025, Israel: Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company aiming to revolutionize the development of
Read More
Evogene
Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases
13 August 2025, Israel: Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the
Read More
Evogene Announces Completion of Transaction for the Sale of Lavie Bio’s Activity to ICL
09 July 2025, Israel: Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology company utilizing cutting-edge artificial intelligence and predictive biology to
Read More
Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud
12 June 2025, Israel: Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing life-science product discovery and
Read More
Evogene Reports First Quarter 2025 Financial Results
22 May 2025, Israel: Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based
Read More
Evogene Schedules First Quarter 2025 Financial Results Release
10 May 2025, Rehovot: Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and
Read More
ICL to Acquire the Activity of Evogene’s subsidiary, Lavie Bio
22 April 2025, Israel: Evogene Ltd., a computational biology company focused on life-science-based product discovery and development announced the signing of a definitive
Read More
Evogene Schedules Fourth Quarter 2024 Financial Results Release
21 February 2025, Rehovot: Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and
Read More
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
14 February 2025, Rehovot: AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of
Read More
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
20 November 2024, Israel: Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced
Read More